MARKET

IMMX

IMMX

Immix Biopharma Inc
NASDAQ
10.97
+0.05
+0.46%
After Hours: 10.97 0 0.00% 19:34 08/14 EDT
OPEN
10.85
PREV CLOSE
10.92
HIGH
11.08
LOW
10.36
VOLUME
1.30M
TURNOVER
--
52 WEEK HIGH
12.14
52 WEEK LOW
1.940
MARKET CAP
784.79M
P/E (TTM)
-12.1028
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: AEON Biopharma (AEON) and Immix Biopharma (IMMX)
TipRanks · 11h ago
Analysts Offer Insights on Healthcare Companies: Immix Biopharma (IMMX), TScan Therapeutics (TCRX) and enGene Holdings (ENGN)
TipRanks · 2d ago
Immix Biopharma Is Maintained at Overweight by Morgan Stanley
Dow Jones · 3d ago
Immix Biopharma Price Target Cut to $19.00/Share From $20.00 by Morgan Stanley
Dow Jones · 3d ago
Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19
Benzinga · 3d ago
Immix Biopharma Price Target Raised to $25.00/Share From $20.00 by HC Wainwright & Co.
Dow Jones · 4d ago
Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 4d ago
HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $25
Benzinga · 4d ago
More
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.

Webull offers Immix Biopharma Inc stock information, including NASDAQ: IMMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMX stock methods without spending real money on the virtual paper trading platform.